<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="oto270132" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">OTO Open</journal-id><journal-id journal-id-type="iso-abbrev">OTO Open</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2473-974X</journal-id><journal-id journal-id-type="publisher-id">OTO2</journal-id><journal-title-group><journal-title>OTO Open</journal-title></journal-title-group><issn pub-type="epub">2473-974X</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12100635</article-id><article-id pub-id-type="doi">10.1002/oto2.70132</article-id><article-id pub-id-type="publisher-id">OTO270132</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Trichloroacetic Acid as a Topical Treatment for Actinic Cheilitis</article-title><alt-title alt-title-type="left-running-head">Kuta and Taylor</alt-title></title-group><contrib-group><contrib id="oto270132-cr-0001" contrib-type="author" corresp="yes"><name><surname>Kuta</surname><given-names>Victoria</given-names></name><degrees>MD, FRCSC</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6083-3598</contrib-id><xref rid="oto270132-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>victoria.kuta@dal.ca</email></address></contrib><contrib id="oto270132-cr-0002" contrib-type="author"><name><surname>Taylor</surname><given-names>S. Mark</given-names></name><degrees>MD, FRCSC, FACS</degrees><xref rid="oto270132-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="oto270132-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Queen Elizabeth II Health Sciences Center, Division of Otolaryngology&#x02013;Head &#x00026; Neck Surgery</named-content>
<institution>Dalhousie University</institution>
<city>Halifax</city>
<country country="CA">Canada</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Corresponding Author:</bold> Victoria Kuta, MD, FRCSC, QEII Health Science Center&#x02010;Victoria General Site 3rd Floor Dickson Building, Division of Otolaryngology, Dalhousie University, 3044&#x02010;5820 University Avenue, Halifax, Nova Scotia, B3H 1V7 Canada.<break/>
Email: <email>victoria.kuta@dal.ca</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><season>Apr-Jun</season><year>2025</year></pub-date><volume>9</volume><issue seq="20">2</issue><issue-id pub-id-type="doi">10.1002/oto2.v9.2</issue-id><elocation-id>e70132</elocation-id><history>
<date date-type="rev-recd"><day>05</day><month>3</month><year>2025</year></date>
<date date-type="received"><day>20</day><month>12</month><year>2024</year></date>
<date date-type="accepted"><day>02</day><month>5</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 The Author(s). OTO Open published by Wiley Periodicals LLC on behalf of American Academy of Otolaryngology&#x02013;Head and Neck Surgery Foundation.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). OTO Open published by Wiley Periodicals LLC on behalf of American Academy of Otolaryngology&#x02010;Head and Neck Surgery Foundation.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:OTO2-9-e70132.pdf"/><abstract><title>Abstract</title><sec id="oto270132-sec-0010"><title>Importance</title><p>Actinic cheilitis is a condition of the lower lip with the potential for malignant transformation. Although many topical treatment options exist, most involve prolonged application periods with expected adverse effects that limit compliance.</p></sec><sec id="oto270132-sec-0020"><title>Objective</title><p>Trichloroacetic acid is a widely used chemical peel that has been used for the treatment of precancerous skin lesions. This study aims to study the efficacy of 35% trichloroacetic acid as a topical treatment for actinic cheilitis.</p></sec><sec id="oto270132-sec-0030"><title>Study Design</title><p>Prospective cohort study of patients with actinic cheilitis presenting to our institution between September 2020 and December 2023. After treatment completion, patients were followed twice yearly for a minimum of 2 years.</p></sec><sec id="oto270132-sec-0040"><title>Setting</title><p>Tertiary care center.</p></sec><sec id="oto270132-sec-0050"><title>Methods</title><p>All patients with actinic cheilitis presenting to an otolaryngologist&#x02010;head and neck surgeon at our institution within the study time frame were eligible. Exclusion criteria include patients &#x0003c;18 years of age, patients who were pregnant, and patients with a biopsy&#x02010;proven malignancy of the lip. A topical 35% trichloroacetic acid peel was applied to the lower lip in the minor procedure clinic following bilateral mental nerve blocks. Patients were brought back 1 month later for follow&#x02010;up &#x000b1; a repeat treatment. Photos were taken prior to treatment and 1 month following their final treatment. The severity of actinic cheilitis was graded using a proposed grading scale for actinic cheilitis, and the burden of the condition was assessed using Skindex&#x02010;16 Surveys. Visual analog scales were used to study adverse events. Patients were monitored for remission and recurrence.</p></sec><sec id="oto270132-sec-0080"><title>Results</title><p>A total of 11 patients were enrolled, with the majority requiring one treatment to achieve clinical remission. All patients who completed their full treatment course entered clinical remission following their trichloroacetic acid treatment, and there have been no cases of recurrence to date. The most common reported side effects were redness and swelling. Patients reported a significant improvement in their quality of life following treatment.</p></sec><sec id="oto270132-sec-0090"><title>Conclusion</title><p>This study suggests that a 35% trichloroacetic acid peel is a safe, well&#x02010;tolerated, and effective treatment option for patients presenting with actinic cheilitis. Further follow&#x02010;up is indicated to study the longevity of the achieved results.</p></sec><sec id="oto270132-sec-0100"><title>Trial Registration</title><p>This study is registered on Clinicaltrials.gov (NCT04744103). <ext-link xlink:href="https://clinicaltrials.gov/study/NCT04744103?locStr=Halifax,%20NS,%20Canada%26country=Canada%26state=Nova%20Scotia%26city=Halifax%26cond=actinic%20cheilitis%26rank=1" ext-link-type="uri">https://clinicaltrials.gov/study/NCT04744103?locStr=Halifax,%20NS,%20Canada&#x00026;country=Canada&#x00026;state=Nova%20Scotia&#x00026;city=Halifax&#x00026;cond=actinic%20cheilitis&#x00026;rank=1</ext-link>.</p></sec></abstract><kwd-group><kwd id="oto270132-kwd-0001">actinic cheilitis</kwd><kwd id="oto270132-kwd-0002">chemical peel</kwd><kwd id="oto270132-kwd-0003">topical treatment</kwd><kwd id="oto270132-kwd-0004">trichloroacetic acid</kwd></kwd-group><counts><fig-count count="3"/><table-count count="1"/><page-count count="5"/><word-count count="3114"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April-June 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.6 mode:remove_FC converted:23.05.2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Actinic cheilitis is a condition of the lower lip characterized by grayish&#x02010;white areas of discoloration and blunting of the demarcation between the cutaneous lip and the mucosa. It is associated with heavy or chronic sun exposure<xref rid="oto270132-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> and is more commonly found in males.<xref rid="oto270132-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> Approximately 10% to 30% of cases undergo malignant transformation to squamous cell carcinoma (SCC), and therefore, treatment is recommended at early presentation stages.<xref rid="oto270132-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> Diagnosis can be clinical, histopathological, or both.</p><p>Although many studies have compared treatment options for actinic cheilitis, there is still significant debate over how to best manage this condition. The chosen treatment regimen must result in complete remission while also preventing recurrence and malignant transformation. Current treatment options are vast, including both nonsurgical and surgical options. Common topical therapies include 5&#x02010;fluorouracil, imiquimod, ingenol mebutate, and diclofenac. More recently, photodynamic therapy has been brought forward as a potential treatment modality. From a surgical perspective, a vermilionectomy is typically the procedure of choice.<xref rid="oto270132-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>
</p><p>Previous studies have reported a higher remission rate with surgical treatment (92.8%) compared to nonsurgical treatments (65.9%). In addition, the recurrence rate is lower for surgical treatment (8.4%) versus nonsurgical treatments (19.2%).<xref rid="oto270132-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> Although these results seem to favor surgical excision of actinic cheilitis, the procedure is not without risk. Patients are subjected to the risk of bleeding and infection, pain, scarring, and dysesthesia. Thus, topical therapies are still an attractive option for many patients.</p><p>Trichloroacetic acid (TCA) is a widely used chemical peel with a vast range of applications, both cosmetic and therapeutic. Topical application of TCA leads to a coagulation of skin protein and destruction of the epidermis and upper dermis layer, followed by regeneration of the dermis and epidermis with the production of new, healthy keratinocytes and new collagen deposition.<xref rid="oto270132-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="oto270132-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>
</p><p>The peeling depth of TCA is dependent on the concentration used. Historically, chemical peels were completed using concentrations of 40% to 60% TCA; however, higher concentrations were found to carry an increased risk of scarring.<xref rid="oto270132-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> Standard TCA applications now range between 30% and 50%, which results in a medium depth peel, penetrating full thickness epidermis and into papillary dermis.<xref rid="oto270132-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> Depending on the desired penetration depth, this standard preparation can be further diluted. A superficial peel, for example, is typically achieved with TCA concentrations between 10% and 30%.<xref rid="oto270132-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>
</p><p>From a therapeutic perspective, TCA is a popular topical treatment for treating fine rhytids, hyperpigmentation, photodamage, and premalignant changes, such as actinic keratoses.<xref rid="oto270132-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="oto270132-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> Despite this, TCA is not commonly used for actinic changes on the lips. Here, we propose an expansion of the application of TCA. This study aims to study the efficacy of 35% TCA as a topical treatment for actinic cheilitis</p><sec sec-type="methods" id="oto270132-sec-0120"><title>Methods</title><p>This was a prospective cohort study of patients with actinic cheilitis presenting to our institution. Institutional research ethics board approvals were obtained from the Nova Scotia Health Authority Research Ethics Board.</p><sec id="oto270132-sec-0130"><title>Patient Selection</title><p>All patients with a clinical diagnosis of actinic cheilitis presenting to the Division of Otolaryngology&#x02013;Head and Neck Surgery at our institution between September 2020 and December 2023 were eligible to participate. Patients were recruited during the initial consultation with their surgeon. Exclusion criteria included patients younger than 18 years, patients who were pregnant, and patients with a biopsy&#x02010;proven malignancy of the lip.</p></sec><sec id="oto270132-sec-0140"><title>Procedure</title><p>After their initial consultation, patients were booked for a minor procedure day. The procedure began with a transoral bilateral mental nerve block completed using a local injection of 1% lidocaine without epinephrine. The 35% TCA was then applied to the lip on a soaked Q&#x02010;Tip. This was rolled over the affected area until the tissue began to turn white, indicating that the TCA had activated on the tissues (<xref rid="oto270132-fig-0001" ref-type="fig">Figure 1</xref>). The area was then neutralized with saline&#x02010;soaked gauze. Patients were instructed to apply Vaseline twice daily to the lower lip during the recovery period and were brought back in 1 month for follow&#x02010;up. Antivirals were not routinely administered before the peel. If a complete clinical remission was not achieved, a second peel was performed. This was completed at 1&#x02010;month intervals for a maximum of three treatments. After achieving clinical remission, patients were followed at 6&#x02010;month intervals to monitor for signs of recurrence. Patients were also counseled on the importance of sun protection for the lips.</p><fig position="float" fig-type="Figure" id="oto270132-fig-0001"><label>Figure 1</label><caption><p>The lower lip during treatment. The white discolouration indicates activated trichloroacetic acid.</p></caption><graphic xlink:href="OTO2-9-e70132-g002" position="anchor" id="jats-graphic-1"/></fig></sec><sec id="oto270132-sec-0150"><title>Variables of Interest</title><p>Photos were taken during the initial consultation and at the 1&#x02010;month follow&#x02010;up after the final treatment. A demographics questionnaire was administered. Patients completed a pretreatment and posttreatment Skindex&#x02010;16 Survey (<xref rid="oto270132-suppl-0001" ref-type="supplementary-material">Supplemental Appendix A1</xref>, available online), a validated measure of the effects of skin disease on quality of life. As there is no validated grading scale for actinic cheilitis, researchers graded the severity of the actinic cheilitis pretreatment and posttreatment using a proposed grading scale published by Poitevin et al (<xref rid="oto270132-suppl-0002" ref-type="supplementary-material">Supplemental Appendix A2</xref>, available online).<xref rid="oto270132-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> Adverse outcomes were evaluated using patient reports on a 10&#x02010;point visual analog scale (VAS).</p></sec><sec id="oto270132-sec-0160"><title>Statistical Analysis</title><p>Descriptive variables were summarized using absolute (n) and relative (%) frequencies for categorical variables and mean and standard deviation (SD) for continuous variables.</p><p>All data were tested for normality using the Shapiro&#x02010;Wilk test. Paired <italic toggle="yes">t</italic> tests were used to evaluate the change in Skindex&#x02010;16 scores and actinic cheilitis grading scores pretreatment and posttreatment, with a mean and SD reported. A <italic toggle="yes">P</italic>&#x02010;value&#x02009;&#x0003c;&#x02009;.05 was considered statistically significant for these analyses.</p><p>Statistical analysis was performed using SPSS software version 29.0.2.0 (SPSS, Inc.).</p></sec></sec><sec sec-type="results" id="oto270132-sec-0170"><title>Results</title><p>A total of 11 patients met the inclusion criteria. The average age was 66.7 years (SD&#x02009;=&#x02009;9.8), and the population was predominantly male (n&#x02009;=&#x02009;7, 64%). All participants identified as Caucasian. The majority of participants categorized their lifetime sun exposure as average (n&#x02009;=&#x02009;6, 55%), and more than half of the population recalled a facial sunburn in their history (n&#x02009;=&#x02009;6, 55%). Baseline characteristics are found in&#x000a0;<xref rid="oto270132-tbl-0001" ref-type="table">Table 1</xref>.</p><table-wrap position="float" id="oto270132-tbl-0001" content-type="Table"><label>Table 1</label><caption><p>Demographic Characteristics and Exposure History of Study Cohort</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="left" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><thead valign="bottom"><tr valign="bottom" style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Demographics</th><th align="center" valign="bottom" rowspan="1" colspan="1">Value</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Age, mean (range), y</td><td align="center" valign="top" rowspan="1" colspan="1">66.7 (47&#x02010;82)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex, no. (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Male</td><td align="center" valign="top" rowspan="1" colspan="1">7 (64)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Female</td><td align="center" valign="top" rowspan="1" colspan="1">4 (36)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Smoking, no. (%)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (18)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Immunocompromised, no. (%)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (18)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sunscreen use, no. (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Never</td><td align="center" valign="top" rowspan="1" colspan="1">2 (18)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Rarely</td><td align="center" valign="top" rowspan="1" colspan="1">2 (18)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Sometimes</td><td align="center" valign="top" rowspan="1" colspan="1">4 (36)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Most times</td><td align="center" valign="top" rowspan="1" colspan="1">1 (9)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Always</td><td align="center" valign="top" rowspan="1" colspan="1">2 (18)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lifetime sun exposure, no. (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Average</td><td align="center" valign="top" rowspan="1" colspan="1">6 (55)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Above average</td><td align="center" valign="top" rowspan="1" colspan="1">4 (36)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">High</td><td align="center" valign="top" rowspan="1" colspan="1">1 (9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Previous facial sunburn, no. (%)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (54)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Previous skin cancer, no. (%)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (27)</td></tr></tbody></table><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>The average pretreatment actinic cheilitis grading was 3.2 (SD&#x02009;=&#x02009;0.8), which improved to an average of 1.1 (SD&#x02009;=&#x02009;0.3; <italic toggle="yes">t</italic>&#x02009;=&#x02009;9.8, <italic toggle="yes">P</italic>&#x02009;=&#x02009;&#x0003c;.001) posttreatment. Our study did include one patient who was graded clinically as a two posttreatment. The clinical team recommended one additional treatment; however, the patient was satisfied with their result and chose not to pursue any further treatment.</p><p>A paired samples <italic toggle="yes">t</italic> test showed that the impact of actinic cheilitis on participants' quality of life significantly decreased from pretreatment (<italic toggle="yes">M</italic>&#x02009;=&#x02009;27.8, SD&#x02009;=&#x02009;21.3) to posttreatment (<italic toggle="yes">M</italic>&#x02009;=&#x02009;6.9, SD&#x02009;=&#x02009;12.9; <italic toggle="yes">t</italic>&#x02009;=&#x02009;2.9, <italic toggle="yes">P</italic>&#x02009;=&#x02009;.014).</p><p>The majority of patients saw resolution of their actinic cheilitis with one treatment (n&#x02009;=&#x02009;8, 73%). The remainder were recommended for a second treatment. All patients who completed this achieved clinical remission (n&#x02009;=&#x02009;2, 18%). The most common complication was swelling (VAS 4.3 [SD&#x02009;=&#x02009;3.2]), followed by redness (VAS 3.5 [SD&#x02009;=&#x02009;3.1]). The average healing time following a treatment was 2.6 weeks (SD&#x02009;=&#x02009;1.1). The lower lip during the acute healing phase can be seen in&#x000a0;<xref rid="oto270132-fig-0002" ref-type="fig">Figure 2</xref>.</p><fig position="float" fig-type="Figure" id="oto270132-fig-0002"><label>Figure 2</label><caption><p>The treated lower lip during the acute healing phase.</p></caption><graphic xlink:href="OTO2-9-e70132-g003" position="anchor" id="jats-graphic-3"/></fig><p>After their final peel, patients were followed twice yearly to monitor for signs of recurrence. None of the patients have experienced a recurrence of their actinic cheilitis to date, and the patient who declined a repeat treatment has remained stable at a grade 2. Before and after photos can be seen in&#x000a0;<xref rid="oto270132-fig-0003" ref-type="fig">Figure 3</xref>.</p><fig position="float" fig-type="Figure" id="oto270132-fig-0003"><label>Figure 3</label><caption><p>Before and after trichloroacetic acid treatment of the lower lip.</p></caption><graphic xlink:href="OTO2-9-e70132-g001" position="anchor" id="jats-graphic-5"/></fig></sec><sec sec-type="discussion" id="oto270132-sec-0180"><title>Discussion</title><p>Actinic cheilitis is a premalignant condition affecting the lower lip. It is considered a chronic condition that typically develops in response to longstanding ultraviolet radiation exposure. The reported risk of malignant transformation ranges between 10% and 30%, making early detection and treatment essential.<xref rid="oto270132-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>
</p><p>SCC of the lip is more aggressive than cutaneous SCC, with a high risk for metastasis.<xref rid="oto270132-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="oto270132-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> The probability of metastasis from cutaneous SCC is 1% compared to 11% for cutaneous SCC of the lower lip.<xref rid="oto270132-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="oto270132-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> Therefore, it is important to treat actinic cheilitis early to reduce this risk for malignant transformation. Current follow&#x02010;up recommendations after actinic cheilitis treatment include twice yearly visits for 2 years followed by annual skin checks after this.<xref rid="oto270132-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>
</p><p>Actinic cheilitis can vary widely in its presentation, ranging from dryness to frank ulceration and crusting. Overt atrophy may be present, and the vermilion border can be poorly defined. There may also be regions of focal hyperkeratosis.<xref rid="oto270132-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>
</p><p>Traditionally, actinic cheilitis has been recognized as a clinical diagnosis. It has been recommended that patients who display exam findings consistent with classic actinic cheilitis should not undergo a biopsy to confirm the diagnosis.<xref rid="oto270132-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> In contrast, persistent and suspicious lesions should undergo biopsy with hematoxylin and eosin staining to rule out malignancy. de Santana Sarmento et al recommended biopsy in the presence of ulcerations/atrophy/nodules, after failure of conservative treatment, or if the area is small and amenable to complete surgical resection.<xref rid="oto270132-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> Basic histopathologic features for actinic cheilitis include hyperkeratosis, solar elastosis, mild to moderate epithelial dysplasia, and perivascular inflammation.<xref rid="oto270132-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> Interestingly, some studies have also suggested a role for biopsy in assessing treatment response. Sotiriou et al report a complete clinical response in 90% of cases with complete histological clearance in only 80%.<xref rid="oto270132-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>
</p><p>The goal of treatment for actinic cheilitis is to reduce the risk of malignant transformation while maintaining lip function and cosmesis. Both medical and surgical options are available. Surgical/ablative techniques include excisional vermilionectomy, electrocautery, laser therapy, or cryotherapy. Although these options achieve high remission rates (92.8%) with a low risk of recurrence (8.4%),<xref rid="oto270132-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> they do come with the associated risk of adverse events including pain, swelling, infection, bleeding, scarring, prolonged healing time, paresthesia, and poor cosmesis. Because of this, surgical vermilionectomy is typically reserved for severe or refractory cases.<xref rid="oto270132-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>
</p><p>Topical treatment is the preferred treatment for patients who have large areas of sun damage in the absence of high&#x02010;risk clinical features.<xref rid="oto270132-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> Many treatments, such as imiquimod and 5&#x02010;fluorouracil, require repeated applications over a period of weeks.<xref rid="oto270132-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> Unfortunately, this prolonged application period, combined with the expected local side effects, decreases patient compliance.<xref rid="oto270132-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="oto270132-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> In contrast, TCA can be applied as a single treatment in the majority of patients. Although TCA has been recognized as a topical treatment option for actinic cheilitis, there is currently very little published data regarding its efficacy. This study provides a unique and prospective look at the use of TCA as a treatment regimen.</p><p>This study is not without its limitations. As mentioned above, our results rely on clinical judgment for both diagnosis and assessment for remission. Although histopathology would aid in this assessment, we did not wish to subject patients to an additional healing period from a punch biopsy, especially in the posttreatment period when the lip appeared clinically normal. Future studies will aim to incorporate dematoscopic evaluation into the encounter as an additional assessment aid. In addition, we do not currently have a validated grading scale for actinic cheilitis severity. Although we utilized the scale proposed by Poitevin et al,<xref rid="oto270132-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> this scale does not have a category for normal lip, and therefore, the best score we could assign was a grade 1. Future research initiatives should include the development of a validated scale that can be applied to both the pretreatment and posttreatment cohorts. Finally, our small sample size with narrow demographic variability limits external validity. Despite these limitations, our study offers an important look into the efficacy and feasibility of TCA as a treatment option for patients with actinic cheilitis.</p></sec><sec sec-type="conclusions" id="oto270132-sec-0190"><title>Conclusion</title><p>This study suggests that topical TCA treatment for actinic cheilitis is both well tolerated and effective at achieving clinical remission. Patients also reported a significant improvement in the effect of their condition on their quality of life. Although we will continue to monitor for recurrence, all patients in this study who completed the full treatment course are currently disease&#x02010;free from a clinical perspective.</p></sec><sec id="oto270132-sec-0200"><title>Author Contributions</title><p>
<bold>Victoria Kuta</bold>, REB, data collection, statistics, manuscript preparation; <bold>S. Mark Taylor</bold>, REB review, TCA peels, patient follow&#x02010;up, manuscript preparation.</p></sec><sec id="oto270132-sec-0210"><title>Disclosures</title><sec sec-type="COI-statement" id="oto270132-sec-0220"><title>Competing interests</title><p>No conflicts to report.</p></sec><sec id="oto270132-sec-0230"><title>Funding source</title><p>No financial support was provided for this study.</p></sec></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="oto270132-suppl-0001" position="float" content-type="local-data"><caption><p>Appendix A1: Skindex&#x02010;16 Survey.</p></caption><media xlink:href="OTO2-9-e70132-s002.docx"/></supplementary-material><supplementary-material id="oto270132-suppl-0002" position="float" content-type="local-data"><caption><p>Appendix A2: Proposed grading scale for actinic cheilitis.</p></caption><media xlink:href="OTO2-9-e70132-s001.docx"/></supplementary-material></sec></body><back><ref-list content-type="cited-references" id="oto270132-bibl-0001"><title>References</title><ref id="oto270132-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="oto270132-cit-0001">
<string-name>
<surname>Gomes</surname>
<given-names>JO</given-names>
</string-name>, <string-name>
<surname>de Vasconcelos Carvalho</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fonseca</surname>
<given-names>FP</given-names>
</string-name>, <string-name>
<surname>Gondak</surname>
<given-names>RO</given-names>
</string-name>, <string-name>
<surname>Lopes</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Vargas</surname>
<given-names>PA</given-names>
</string-name>. <article-title>CD1a+ and CD83 + Langerhans cells are reduced in lower lip squamous cell carcinoma</article-title>. <source>J Oral Pathol Med</source>. <year>2016</year>;<volume>45</volume>(<issue>6</issue>):<fpage>433</fpage>&#x02010;<lpage>439</lpage>.<pub-id pub-id-type="pmid">26661374</pub-id>
</mixed-citation></ref><ref id="oto270132-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="oto270132-cit-0002">
<string-name>
<surname>Miranda</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Soares</surname>
<given-names>LG</given-names>
</string-name>, <string-name>
<surname>Ferrari</surname>
<given-names>TM</given-names>
</string-name>, <string-name>
<surname>Silva</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Falabella</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Tinoco</surname>
<given-names>EM</given-names>
</string-name>. <article-title>Prevalence of actinic cheilitis in a population of agricultural sugarcane workers</article-title>. <source>Acta Odontolog Latinoam</source>. <year>2012</year>;<volume>25</volume>(<issue>2</issue>):<fpage>201</fpage>&#x02010;<lpage>206</lpage>.</mixed-citation></ref><ref id="oto270132-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="oto270132-cit-0003">
<string-name>
<surname>Lopes</surname>
<given-names>MLDS</given-names>
</string-name>, <string-name>
<surname>Silva J&#x000fa;nior</surname>
<given-names>FL</given-names>
</string-name>, <string-name>
<surname>Lima</surname>
<given-names>KC</given-names>
</string-name>, <string-name>
<surname>Oliveira</surname>
<given-names>PT</given-names>
</string-name>, <string-name>
<surname>Silveira</surname>
<given-names>&#x000c9;JD</given-names>
</string-name>. <article-title>Clinicopathological profile and management of 161 cases of actinic cheilitis</article-title>. <source>An Bras Dermatol</source>. <year>2015</year>;<volume>90</volume>(<issue>4</issue>):<fpage>505</fpage>&#x02010;<lpage>512</lpage>.<pub-id pub-id-type="pmid">26375219</pub-id>
</mixed-citation></ref><ref id="oto270132-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="oto270132-cit-0004">
<string-name>
<surname>Salgueiro</surname>
<given-names>AP</given-names>
</string-name>, <string-name>
<surname>de Jesus</surname>
<given-names>LH</given-names>
</string-name>, <string-name>
<surname>de Souza</surname>
<given-names>IF</given-names>
</string-name>, <string-name>
<surname>Rados</surname>
<given-names>PV</given-names>
</string-name>, <string-name>
<surname>Visioli</surname>
<given-names>F</given-names>
</string-name>. <article-title>Treatment of actinic cheilitis: a systematic review</article-title>. <source>Clin Oral Investig</source>. <year>2019</year>;<volume>23</volume>(<issue>5</issue>):<fpage>2041</fpage>&#x02010;<lpage>2053</lpage>.</mixed-citation></ref><ref id="oto270132-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="oto270132-cit-0005">
<string-name>
<surname>Carvalho</surname>
<given-names>MV</given-names>
</string-name>, <string-name>
<surname>de Moraes</surname>
<given-names>SLD</given-names>
</string-name>, <string-name>
<surname>Lemos</surname>
<given-names>CAA</given-names>
</string-name>, <string-name>
<surname>Santiago J&#x000fa;nior</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Vasconcelos</surname>
<given-names>BCE</given-names>
</string-name>, <string-name>
<surname>Pellizzer</surname>
<given-names>EP</given-names>
</string-name>. <article-title>Surgical versus non&#x02010;surgical treatment of actinic cheilitis: a systematic review and meta&#x02010;analysis</article-title>. <source>Oral Dis</source>. <year>2019</year>;<volume>25</volume>(<issue>4</issue>):<fpage>972</fpage>&#x02010;<lpage>981</lpage>.<pub-id pub-id-type="pmid">29908101</pub-id>
</mixed-citation></ref><ref id="oto270132-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="oto270132-cit-0006">
<string-name>
<surname>Vavouli</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Katsambas</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Gregoriou</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Chemical peeling with trichloroacetic acid and lactic acid for infraorbital dark circles</article-title>. <source>J Cosmet Dermatol</source>. <year>2013</year>;<volume>12</volume>(<issue>3</issue>):<fpage>204</fpage>&#x02010;<lpage>209</lpage>.<pub-id pub-id-type="pmid">23992162</pub-id>
</mixed-citation></ref><ref id="oto270132-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="oto270132-cit-0007">
<string-name>
<surname>Fischer</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Perosino</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Poli</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Viera</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Dreno</surname>
<given-names>B</given-names>
</string-name>, <collab collab-type="authors">Cosmetic Dermatology European Expert Group</collab>
. <article-title>Chemical peels in aesthetic dermatology: an update 2009</article-title>. <source>J Eur Acad Dermatol Venereol</source>. <year>2010</year>;<volume>24</volume>(<issue>3</issue>):<fpage>281</fpage>&#x02010;<lpage>292</lpage>.<pub-id pub-id-type="pmid">19744174</pub-id>
</mixed-citation></ref><ref id="oto270132-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="oto270132-cit-0008">
<string-name>
<surname>Poitevin</surname>
<given-names>NA</given-names>
</string-name>, <string-name>
<surname>Rodrigues</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Weigert</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Macedo</surname>
<given-names>CLR</given-names>
</string-name>, <string-name>
<surname>Dos Santos</surname>
<given-names>RB</given-names>
</string-name>. <article-title>Actinic cheilitis: proposition and reproducibility of a clinical criterion</article-title>. <source>BDJ Open</source>. <year>2017</year>;<volume>3</volume>:<elocation-id>17016</elocation-id>.<pub-id pub-id-type="pmid">29607086</pub-id>
</mixed-citation></ref><ref id="oto270132-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="oto270132-cit-0009">
<string-name>
<surname>Tse</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ostad</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>HS</given-names>
</string-name>, et al. <article-title>Clinical and histologic evaluation of two medium&#x02010;depth peels: glycolic acid versus Jessner's trichloroacetic acid</article-title>. <source>Dermatol Surg</source>. <year>1996</year>;<volume>22</volume>(<issue>9</issue>):<fpage>781</fpage>&#x02010;<lpage>786</lpage>.<pub-id pub-id-type="pmid">8874526</pub-id>
</mixed-citation></ref><ref id="oto270132-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="oto270132-cit-0010">
<string-name>
<surname>Soleymani</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Lanoue</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Rahman</surname>
<given-names>Z</given-names>
</string-name>. <article-title>A practical approach to chemical peels. A review of fundamentals and step&#x02010;by&#x02010;step algorithmic protocol for treatment</article-title>. <source>J Clin Aesthet Dermatol</source>. <year>2018</year>;<volume>11</volume>(<issue>8</issue>):<fpage>21</fpage>&#x02010;<lpage>28</lpage>.</mixed-citation></ref><ref id="oto270132-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="oto270132-cit-0011">
<string-name>
<surname>Brancaccio</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Fargnoli</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Briatico</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Pellegrini</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Rocco</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Moscarella</surname>
<given-names>E</given-names>
</string-name>. <article-title>Risk factors and diagnosis of advanced cutaneous squamous cell carcinoma</article-title>. <source>Dermatol Pract Concept</source>. <year>2021</year>;<volume>11</volume>(<issue>suppl 2</issue>):<elocation-id>e2021166S</elocation-id>.<pub-id pub-id-type="pmid">34877074</pub-id>
</mixed-citation></ref><ref id="oto270132-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="oto270132-cit-0012">
<string-name>
<surname>Knuutila</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Riihil&#x000e4;</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Kurki</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Nissinen</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>K&#x000e4;h&#x000e4;ri</surname>
<given-names>V</given-names>
</string-name>. <article-title>Risk factors and prognosis for metastatic cutaneous squamous cell carcinoma: a cohort study</article-title>. <source>Acta Derm Venereol</source>. <year>2020</year>;<volume>100</volume>(<issue>16</issue>):<elocation-id>adv00266</elocation-id>.<pub-id pub-id-type="pmid">32930344</pub-id>
</mixed-citation></ref><ref id="oto270132-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="oto270132-cit-0013">
<string-name>
<surname>Barrado Sol&#x000ed;s</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Mol&#x000e9;s Poveda</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lloret Ruiz</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Ingenol mebutate gel treatment for actinic cheilitis: report of four cases</article-title>. <source>Dermatol Ther</source>. <year>2015</year>;<volume>28</volume>(<issue>2</issue>):<fpage>79</fpage>&#x02010;<lpage>82</lpage>.<pub-id pub-id-type="pmid">25545762</pub-id>
</mixed-citation></ref><ref id="oto270132-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="oto270132-cit-0014">
<string-name>
<surname>Zhang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Trends in cutaneous squamous cell carcinoma on the lip incidence and mortality in the United States, 2000&#x02010;2019</article-title>. <source>Front Oncol</source>. <year>2023</year>;<volume>13</volume>:<elocation-id>1111907</elocation-id>.<pub-id pub-id-type="pmid">37139158</pub-id>
</mixed-citation></ref><ref id="oto270132-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="oto270132-cit-0015">
<string-name>
<surname>Rezende</surname>
<given-names>HD</given-names>
</string-name>, <string-name>
<surname>Oliveira</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Campos</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Fukuma</surname>
<given-names>LO</given-names>
</string-name>, <string-name>
<surname>Delgado</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Dinato</surname>
<given-names>SLM</given-names>
</string-name>. <article-title>Actinic cheilitis or squamous cell carcinoma of the lip? Practical recommendations on how to avoid a trap</article-title>. <source>Rev Assoc Med Bras</source>. <year>2022</year>;<volume>68</volume>(<issue>7</issue>):<fpage>877</fpage>&#x02010;<lpage>878</lpage>.<pub-id pub-id-type="pmid">35946758</pub-id>
</mixed-citation></ref><ref id="oto270132-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="oto270132-cit-0016">
<string-name>
<surname>de Santana Sarmento</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>da Costa Miguel</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Queiroz</surname>
<given-names>LMG</given-names>
</string-name>, <string-name>
<surname>Godoy</surname>
<given-names>GP</given-names>
</string-name>, <string-name>
<surname>da Silveira</surname>
<given-names>&#x000c9;JD</given-names>
</string-name>. <article-title>Actinic cheilitis: clinicopathologic profile and association with degree of dysplasia</article-title>. <source>Int J Dermatol</source>. <year>2014</year>;<volume>53</volume>(<issue>4</issue>):<fpage>466</fpage>&#x02010;<lpage>472</lpage>.<pub-id pub-id-type="pmid">24320079</pub-id>
</mixed-citation></ref><ref id="oto270132-bib-0017"><label>17</label><mixed-citation publication-type="book" id="oto270132-cit-0017">
<string-name>
<surname>Muse</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Crane</surname>
<given-names>JS</given-names>
</string-name>. <part-title>Actinic cheilitis [updated 2023 Jul 31]</part-title>. In: <source>StatPearls [Internet]</source>. <publisher-name>StatPearls Publishing</publisher-name>; <year>2024</year>.</mixed-citation></ref><ref id="oto270132-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="oto270132-cit-0018">
<string-name>
<surname>Sotiriou</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Apalla</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Koussidou&#x02010;Erremonti</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ioannides</surname>
<given-names>D</given-names>
</string-name>. <article-title>Actinic cheilitis treated with one cycle of 5&#x02010;aminolaevulinic acid&#x02010;based photodynamic therapy: report of 10 cases</article-title>. <source>Br J Dermatol</source>. <year>2008</year>;<volume>159</volume>:<fpage>261</fpage>&#x02010;<lpage>262</lpage>.<pub-id pub-id-type="pmid">18489592</pub-id>
</mixed-citation></ref><ref id="oto270132-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="oto270132-cit-0019">
<string-name>
<surname>Lai</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Pampena</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Cornacchia</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Pellacani</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Peris</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Longo</surname>
<given-names>C</given-names>
</string-name>. <article-title>Treatments of actinic cheilitis: a systematic review of the literature</article-title>. <source>J Am Acad Dermatol</source>. <year>2020</year>;<volume>83</volume>(<issue>3</issue>):<fpage>876</fpage>&#x02010;<lpage>887</lpage>.<pub-id pub-id-type="pmid">31400450</pub-id>
</mixed-citation></ref><ref id="oto270132-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="oto270132-cit-0020">
<string-name>
<surname>Smith</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Germain</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yeager</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Skelton</surname>
<given-names>H</given-names>
</string-name>. <article-title>Topical 5% imiquimod for the therapy of actinic cheilitis</article-title>. <source>J Am Acad Dermatol</source>. <year>2002</year>;<volume>47</volume>(<issue>4</issue>):<fpage>497</fpage>&#x02010;<lpage>501</lpage>.<pub-id pub-id-type="pmid">12271290</pub-id>
</mixed-citation></ref></ref-list></back></article>